Evidence map›Paper›PMID 32775482›Full record

ArticleBladder (San Francisco, Calif.)2020

Biomarker discovery and beyond for diagnosis of bladder diseases.

Sungyong Jung, Jayoung Kim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder (San Francisco, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Sungyong JungDepartment of Electrical Engineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Jayoung KimDepartments of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
The University of Texas at Arlington · USUniversity of California, Los Angeles · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
West Coast Central Comprehensive Metabolomics Resource Core (WC3MRC)U24DK097154 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FIEHN, OLIVER · 2012 to 2017
$9.9M
Microbiome and Proteome As Predictive Biomarkers of UCPPSU01DK103260 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI ANGER, JENNIFER TASH, FREEMAN, MICHAEL R · 2014 to 2018
$1.2M
Urinary Metabolites in IC PBS DiagnosisR01DK100974 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI ANGER, JENNIFER TASH, KIM, JAYOUNG · 2013 to 2013
$416k
NCATS NIH HHS UL1 TR000124NCCDPHP CDC HHS U01 DP006079NIDDK NIH HHS R01 DK100974NIDDK NIH HHS U01 DK103260NIDDK NIH HHS U24 DK097154
6 · The paper itself

Abstract

Molecular biosignatures of altered cellular landscapes and functions have been casually linked with pathological conditions, which imply the promise of biomarkers specific to bladder diseases, such as bladder cancer and other dysfunctions. Urinary biomarkers are particularly attractive due to costs, time, and the minimal and noninvasive efforts acquiring urine. The evolution of omics platforms and bioinformatics for analyzing the genome, epigenome, transcriptome, proteome, lipidome, metabolome,

Indexed as

biomarkerbiosensorbladdermedical deviceurine

Identifiers

PMID32775482
PMCPMC7401981
OpenAlexW3012678566

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.